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Objective: This study evaluated the outcome of intensity-modulated radiation therapy with
simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer.
Methods: We analyzed 53 consecutive nasopharyngeal cancer patients who received defini-
tive treatment using intensity-modulated radiation therapy with simultaneous integrated boost
and cisplatin-based concurrent chemotherapy. Forty-six patients were treated with concurrent
chemoradiation and seven patients with induction chemotherapy plus concurrent chemoradia-
tion. The gross tumor (PTV70) received 69.96 Gy (2.12 Gy/fraction), high-risk subclinical
disease (PTV60) received 59.4 Gy (1.8 Gy/fraction) and low-risk subclinical disease (PTV56)
received 56.1 Gy (1.7 Gy/fraction) in 33 fractions. Twenty-eight patients were treated with
step-and-shoot intensity-modulated radiation therapy and 25 patients with helical tomother-
apy. Dosimetric parameters were compared between the two modalities.
Results: The median treatment duration was 49 days (range: 41–65 days). The complete re-
sponse rate was 92.5%. Three local, two regional, one locoregional and seven distant failures
were observed. With the median follow-up of 41 months (range: 8–89 months), the 3- and 5-
year local control, locoregional control, disease-free survival and overall survival rates were
91.8 and 91.8%; 87.6 and 87.6%; 77.5 and 70.5%; and 86.4 and 82.1%, respectively. Grade
3 mucositis, dermatitis, leucopenia and grade 4 leucopenia were observed in 10, 1, 2 and 1
patient, respectively. No grade 3 or higher xerostomia occurred. Helical tomotherapy signifi-
cantly improved dosimetric parameters including the maximum dose, volume receiving
.107% of the prescribed dose and uniformity index (D5/D95).
Conclusions: Intensity-modulated radiation therapy with simultaneous integrated boost with
concurrent chemotherapy is a safe and effective treatment modality for nasopharyngeal
cancer. Helical tomotherapy has a dosimetric advantage over step-and-shoot intensity-
modulated radiation therapy in a clinical setting.
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INTRODUCTION
Nasopharyngeal carcinoma (NPC) has characteristics distin-
guishable from other head and neck cancers (HNCs) with
respect to epidemiology, clinical features, treatment strat-
egies and response to therapy. NPC is highly endemic in
Southeast Asia, with the predominance of the non-
keratinizing undifferentiated (WHO type IIb) tumor hist-
ology (1). Although NPC is radiosensitive and the addition
of chemotherapy added survival advantage in locoregionally
advanced NPC (2,3), conventional radiotherapy (RT) still
resulted in relatively frequent local failures with a 5-year
local control rate among patients with T3/T4 NPC ranging
from 69 to 79% (4,5). Local control for NPC is strongly cor-
related with the radiation dose delivered to the tumor. In a
series of 107 patients with NPC, local control was signiﬁ-
cantly improved when .67 Gy was delivered to the tumor
(6). At many centers, intensity-modulated radiation therapy
(IMRT) has become the standard RT technique for treating
NPC. IMRT provided better tumor coverage, with a greater
percentage of the target volume receiving the planned pre-
scription dose than a conventional 3D conformal plan (7,8),
and published clinical outcomes demonstrated that IMRT
could produce high local and regional control rates in the
treatment of NPC (9,10).
Simultaneous integrated boost (SIB) technique delivers
various fractional doses to different target volumes in a single
phase plan. Incorporating moderate hypofractionation is ad-
vantageous in that the reduced overall treatment time can
counteract the accelerated tumor repopulation and a larger
fractional dose is more effective in eliminating the cancer
stem cells, which are intrinsically more radioresistant (11,12).
However, hypofractionation and SIB both have a risk of deli-
vering high-dose radiation to adjacent normal organs and
these techniques are best incorporated into IMRT, which can
deliver highly conformal radiation to the tumor and maximize
the therapeutic window. Helical tomotherapy (HT) is a novel
and highly accurate apparatus for delivering IMRT with the
image-guided support of onboard megavoltage computed tom-
ography (CT). Because of its 3608 arrangement of intensity-
modulated narrow beams passing through binary multileaf
collimators (MLCs), HT plans can provide equal or better
dose distribution compared with conventional step-and-shoot
IMRT (ssIMRT) plans. It has been reported that HT provides
improved dose homogeneity to the target and avoidance of
normal structures when compared with ssIMRT in the treat-
ment of many types of cancers including retroperitoneal
sarcoma (13), endometrial carcinoma (14), cranio-spinal
tumor (15) and HNC (16,17). HT also showed a signiﬁcant
dosimetric gain in the conformity index, homogeneity index
and sparing of organs at risk (OARs) when compared with
ssIMRT in the treatment of NPC (18).
The current study reports the treatment outcome of 53
NPC patients treated with IMRT-SIB and concurrent chemo-
therapy and compares dosimetric parameters between
ssIMRT and HT in a clinical setting.
PATIENTS AND METHODS
PATIENTS
We analyzed 53 consecutive patients with biopsy proven,
previously untreated stages IIB–IVB nasopharyngeal cancer
who received a deﬁnitive treatment using IMRT with concur-
rent chemotherapy at the Yonsei Cancer Center, Severance
Hospital between January 2002 and December 2008. All
patients underwent ﬁberoptic nasopharyngoscopy and biopsy
for pathological diagnosis. The initial staging evaluation
included a clinical examination and CT and/or magnetic res-
onance imaging (MRI) of the head and neck, chest radiog-
raphy, abdominal sonography or CT, complete blood count
with differential count and biochemical proﬁle. Some
patients underwent positron emission tomography for sys-
temic assessment. Staging of nasopharyngeal cancer was
based on the TNM system of the American Joint Committee
on Cancer, 6th edition.
RADIATION THERAPY
For CT simulation, patients were immobilized in a supine
position with custom head and shoulder Aquaplast masks
(Aquaplast, Wycoff, NJ), and CT images were obtained
every 3 mm extending from the vertex to 5-cm inferior to
the clavicular heads. The target volume and normal tissue
structures were contoured on each axial CT slice, supple-
mented with fused diagnostic MRI and/or PET scans. Both
ssIMRT and HT plans followed the same target and normal
organ delineation protocol and dose prescriptions. SIB tech-
nique was used for treatment planning. The gross target
volume (PTV70) consisted of the gross primary tumor, the
whole nasopharynx and positive lymph nodes, as deﬁned by
MRI and/or CT, plus a 0.5-cm margin. The high-risk sub-
clinical disease (PTV60) encompassed PTV70 plus a 1.5-cm
margin, potential spread of microscopic disease (including
the parapharyngeal space, posterior third of nasal cavities
and maxillary sinuses, pterygoid processes, base of skull and
lower half of sphenoid sinus), and the prophylactic area of
the neck (including bilateral retropharyngeal nodes, levels II,
III and IV). The low-risk subclinical disease (PTV56)
included the remaining levels (IV-VB) of the neck. In cases
of induction chemotherapy (IC), disease extents in pre-
chemotherapy MRI images were used for target delineation.
OARs outlined in three dimensions included the brainstem,
spinal cord, lenses, eyes, optic chiasm, optic nerves, cochlea
and parotid glands. PTV70 received a total dose of 69.96 Gy
in daily fractions of 2.12 Gy, PTV60 received 59.4 Gy in
1.8 Gy per daily fraction and PTV56 received 56.1 Gy in
1.7 Gy per daily fraction. The dose constraints for OARs
were as follows: a maximum dose of 54 Gy for the brain-
stem, optic nerve and optic chiasm; a maximum dose of
45 Gy for the spinal cord; a maximum dose of 70 Gy for the
mandible; a mean dose of ,26 Gy or dose to 50% of the
Jpn J Clin Oncol 2012;42(12) 1153
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parotid volume (D50%) ,30 Gy for the parotid gland and a
mean dose of ,50 Gy for the inner ear.
For ssIMRT, inverse planning was performed for each
patient using CORVUS, version 5.0 (Nomos Corp.,
Sewickley, PA) and treatment was delivered using
PRIMART (Siemens, CA) linear accelerator with 1-cm
MLC. A standard coplanar 7- or 9-ﬁeld gantry arrangement
was used for designing all ssIMRT plans. Beam orientation
was carefully chosen to achieve optimal parotid sparing. For
HT, inverse planning was performed using the Tomotherapy
Hi-Art System, version 2.0 (TomoTherapy, Madison, WI).
Other parameters for tomotherapy planning included a ﬁeld
width of 2.5 cm, a pitch of 0.3 (distance traveled by the
couch during one complete rotation of the gantry divided by
the ﬁeld width), and a modulation factor of 3.0 (a ratio of
the maximum and average number of opening of the leaves
in active gantry rotations). Both planning systems used
least-square minimization as cost functions. Doses to OARs
were optimized on an individual basis by a maximum dose
constraints set without compromising the PTV coverage,
with at least 95% of the PTV receiving the minimum pre-
scribed dose.
DOSIMETRIC COMPARISON BETWEEN SSIMRT AND HT PLANS
The two planning systems use different algorithms for dose
calculation. CORVUS for ssIMRT planning uses ﬁnite-sized
pencil beam algorithms and the work of Nizin (19), while
the Hi-Art system for HT uses superposition convolution al-
gorithm for dose calculation. We used heterogeneity correc-
tion options for both planning systems. The following
parameters were chosen for PTV70 and PTV60 to evaluate
the efﬁcacy of IMRT planning and compare the treatment
plans between ssIMRT and HT: a maximum dose (Dmax),
minimum dose (Dmin), PTV receiving .95% of the pre-
scribed dose (V95%) and PTV receiving .107% of the pre-
scribed dose (V107%). In order to assess the uniformity of
both plans, we used a uniformity index (UI), deﬁned as the
ratio between D5 and D95, where D5 and D95 are the
minimum doses delivered to 5 and 95% of the PTV,
respectively.
CHEMOTHERAPY
Chemotherapy administered concurrently with external beam
radiotherapy included weekly cisplatin 30 mg/m2 (DDP),
weekly cisplatin 20 mg/m2 plus 5-ﬂuorourcil (FU) 750 mg/m2
(FP) and 5-FU 750 mg/m2 plus taxotere 70 mg/m2 plus cis-
platin 75 mg/m2 every third week (FTP). Radiotherapy with
concurrent cisplatin has been the standard treatment for naso-
pharyngeal cancer in our institution since 2006. Before 2006,
chemotherapy regimens were decided according to physi-
cians’ discretion, with the preference of FTP or FT regimens
for more advanced disease including T3 stage or N (þ)
disease. The IC regimen consisted of cisplatin at a dose of
75 mg/m2 and 5-FU at 1000 mg/m2 for 5 days (on days 1–5),
repeated every 3 weeks, and followed by the concurrent che-
moradiation (CCRT) regimens beginning 3 weeks after the
third course of IC. Complete blood counts and blood chemis-
try were checked at least once a week and before each chemo-
therapy cycle. Dose modiﬁcations were allowed based on
blood counts and toxicities from preceding cycles.
FOLLOW-UP
The tumor response was assessed according to the World
Health Organization (WHO) criteria, and acute and toxicities
according to Radiation Therapy Oncology Group (RTOG)
criteria. After completion of treatment, patients were fol-
lowed up at the ﬁrst, third and sixth month, and every 6
months thereafter. Physical examination, complete blood
count, blood chemistry were performed at each visit, along
with head and neck CT or MRI, chest radiography and PET
or whole body bone scan every 6 months. Patients were eval-
uated for treatment response by nasopharyngoscopy and
head and neck CT or MRI at the ﬁrst, third and sixth month
after completion of treatment. Biopsy was performed when
residual disease or recurrence was suspected.
STATISTICAL ANALYSIS
Local failure-free survival (LFFS), locoregional failure-free
survival (LRFFS), disease-free survival (DFS) and overall
survival (OS) were measured from the beginning of
radiotherapy. Descriptive statistics (mean, median and pro-
portions) were used to characterize the patients, disease
and treatment features, as well as toxicity after treatment.
The probability of failure due to local disease, distant pro-
gression and death were estimated using the Kaplan–
Meier method. An independent t-test was used to compare
the dosimetric parameters between ssIMRT and HT. P
values of ,0.05 were considered having statistical
signiﬁcance.
RESULTS
PATIENT CHARACTERISTICS
The median follow-up periods were 41 months (range: 8–
89). Table 1 details patient characteristics. Median age was
45 years (range: 16–67), and the 35 male and 18 female
were treated (66 vs. 34%). Two patients were diagnosed with
keratinizing squamous cell carcinoma (WHO type I), 11
patients with non-keratinizing differentiated carcinoma
(WHO type IIa), and 40 patients with non-keratinizing undif-
ferentiated carcinoma (WHO type IIb). The numbers of
patients with stage IIB, III, IVA, and IVB disease were 8,
24, 14 and 7 respectively. Forty-six patients underwent
CCRT with weekly DDP in 36 patients, weekly FP in 6
patients, and FTP in 11 patients. Seven patients were treated
with IC plus CCRT (IC þ CCRT): IC was decided because
radiotherapy was delayed due to pre-RT dental care or
1154 SIB-IMRT with concurrent chemotherapy for NPC
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breakdown of IMRT machine in six patients and because of
multiple large lymph node metastases in one patient. After
introduction of HT in 2006, all nasopharyngeal cancer
patients were treated using HT. Twenty-eight patients were
treated with ssIMRT and 25 patients with HT.
TREATMENT RESPONSE AND SURVIVAL
At the time of analysis, 44 out of 53 patients (83%)
remained alive. Forty-nine patients (92.5%) showed a com-
plete clinical and radiographic response (CR) at 3 months
after initial treatment. Two patients showed a partial re-
sponse: one remained with stable disease without further
treatment and the other patient, who initially presented with
left carotid artery invasion, died of massive bleeding from
the treatment site 8 months after treatment. The remaining
two patients had progressive disease. The 3- and 5-year
Kaplan–Meier estimates for LFFS, LRFFS, DFS and OS
were 91.8 and 91.8%; 87.6 and 87.6%; 77.5 and 70.5% and
86.4 and 82.1%, respectively (Fig. 1A–D).
FAILURE PATTERN ANALYSIS
A total of 13 treatment failures occurred: three local, two re-
gional, one locoregional and seven distant failures (Table 2).
All local/regional failures were in the regions that received
70 Gy (PTV70). Two patients showed progressive disease
after initial treatment: a 60-year-old male, progressed at the
primary site (PTV70) after CCRT and received salvage che-
moradiation, and a 39-year-old male progressed at a cervical
nodal site (PTV70) after IC þ CCRT and received salvage
chemotherapy. Both patients died of progressive disease
despite salvage treatments. The other 11 patients gained CR
initially but showed treatment failure during the follow-up.
A 37-year-old male with T2bN2 disease failed locally (naso-
pharynx, in the PTV70 region) 13 months after CCRT and
died from distant metastasis despite a partial response to
salvage chemoradiation. A 62-year-old female, initially
staged T3N1, failed locally (skull base, in the PTV70 region)
3 months after IC þ CRT, progressed after salvage chemo-
therapy but was still alive at the time of analysis. A
51-year-old male with regional failure (left neck level II, in
PTV70) had been staged initially T4N1 and recurred 30
months after treatment. He is alive and free of disease after
salvage neck dissection and adjuvant chemoradiation. A
42-year-old male staged T3N2, failed locoregionally (clivus,
in PTV70; left neck level II, in PTV70) at 32 months, and is
alive with stable disease after salvage chemoradiation. Seven
patients showed distant metastases at 4–48 months (median:
21) after treatment: three in the lungs, two in the chest wall,
one in the liver and one in multiple sites. A 44-year-old
male with a solitary lung metastasis is alive without disease
after salvage resection, and other two lung-metastasis
patients, a 33-year-old male and 58-year-old female, are
alive with stable disease after salvage chemoradiation. The
rest of the patients with distant metastasis expired despite
various salvage efforts.
DOSE–VOLUME ANALYSIS
Dose–volume histograms (DVH) of the PTVs and critical
organs were analyzed. The mean V95% for PTV70 and PTV60
Table 1. Patient characteristics (n ¼ 53)
Characteristics No. of patients %
Age Median: 45 years Range: 16–67 years
Sex
Male 35 66
Female 18 34
Pathology type
WHO I 2 3.8
WHO IIa 11 20.8
WHO IIb 40 75.5
T stage
T1 14 26.4
T2a 5 9.4
T2b 10 18.9
T3 9 17.0
T4 15 28.3
N stage
N0 1 1.9
N1 20 37.7
N2 25 47.2
N3 7 13.2
Stage
IIB 8 15.1
III 24 45.3
IVA 14 26.4
IVB 7 13.2
Treatment
CCRT 46 86.8
IC þ CCRT 7 13.2
Chemotherapy
DDP 36 67.9
FP 6 11.3
FTP 11 20.8
Radiotherapy
ssIMRT 28 52.8
HT 25 47.2
WHO, World Health Organization; CCRT, concurrent chemoradiation;
IC þ CCRT, induction chemotherapy followed by CCRT; DDP, cisplatin;
FP, 5-ﬂuorouracil plus cisplatin; FTP, 5-ﬂuorouracil plus taxotere plus
cisplatin; ssIMRT, step-and-shoot intensity modulated radiotherapy; HT,
helical tomotherapy.
Jpn J Clin Oncol 2012;42(12) 1155
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were 98.8 and 96.3%. The mean V107% for PTV70 and
PTV60 were 35.3 and 57.7%. The average maximum and
minimum doses were 80.2 and 56.4 Gy for PTV70 and 79.3
and 33.4 Gy for PTV60. The median UI was 1.12 for PTV70
and 1.25 for PTV60 (Table 3). Table 4 lists dose distribution
to normal OARs. The maximum dose was calculated for
serial normal organs. The median maximum doses to the
spinal cord, brain stem, optic chiasm, right inner ear and left
inner ear were 41.1, 50.8, 37.9, 43.8 and 43.9 Gy, respective-
ly. The median mean dose was 21.8 Gy to the right parotid
gland and 22.0 Gy to the left parotid gland.
ACUTE AND LATE TOXICITY
All of the 53 patients completed their full course of radio-
therapy. The median treatment duration was 49 days
Figure 1. Kaplan–Meier estimated local control with numbers at risk (A), locoregional control with numbers at risk (B), disease-free survival with numbers
at risk (C) and overall survival with numbers at risk (D).
Table 2. Treatment failures and results of salvage treatment
Sex/age Stage WHO type Chemo Initial response Failure site Recurrence time (months) Salvage Tx Last F/U OS (months)
M/37 T2bN2 IIa CCRT CR Local (PTV70) 13 CRT DOD 24
M/60 T2aN1 IIb CCRT PD Local (PTV70) 7 CRT DOD 25
F/62 T3N1 IIb IC þ CCRT CR Local (PTV70) 6 Chemo AWD 46
M/51 T4N1 IIb CCRT CR Regional (PTV70) 30 OP þ CRT NED 42
M/39 T1N3b IIb IC þ CCRT PD Regional (PTV70) 3 Chemo DOD 22
M/42 T3N2 IIb CCRT CR Locoregional (PTV70) 32 CRT AWD 38
M/33 T2aN1 IIb CCRT CR Chest wall 37 OP þ CRT DOD 79
M/44 T2bN2 IIb CCRT CR Lung, single 48 OP NED 81
F/49 T1N2 IIa CCRT CR Mediastinum, abdomen 21 Chemo DOD 49
F/33 T2N3a IIb CCRT CR Chest wall 4 CRT AWD 47
M/58 T1N1 IIb IC þ CCRT CR Liver, LNs 31 Chemo AWD 47
F/67 T4N1 IIb CCRT CR Lung, multiple 15 Chemo DOD 24
M/53 T4N1 IIb CCRT CR Lung, multiple 18 Refuse DOD 26
WHO, World Health Organization; CCRT, concurrent chemoradiation; IC þ CCRT, induction chemotherapy followed by CCRT; CR, complete remission; PD,
progressive disease; CRT, chemoradiation; DOD, died of disease; AWD, alive with disease; NED, no evidence of disease.
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(range: 41–65 days). Five patients experienced a treatment
break of 4–7 days due to acute mucositis, two patients
experienced 4 and 7 days of a treatment break due to
acute dermatitis, and one patient rested for 2 weeks due to
neutropenic fever. Acute and late toxicity by site and
grade according to the RTOG criteria are listed in Table 5.
For acute toxicity, Grade 3 mucositis, dermatitis and leuco-
penia were observed in 10, 1 and 2 patients, respectively.
Only one patient suffered Grade 4 leucopenia due to
chemotherapy. No other Grade 4 acute toxicity was
observed. For late toxicity, 14 patients suffered Grade 2
xerostomia. One patient died of massive bleeding from the
treatment site 8 months after CCRT. He had been initially
diagnosed of T4N2 disease with the left carotid artery in-
vasion and bilateral lymph node metastases including the
left level II lymph nodes.
SSIMRT VERSUS HT
Table 3 shows the comparison of DVH parameters between
the two groups of patients who were treated with ssIMRT
(n ¼ 28) and HT (n ¼ 25). For both PTV70 and PTV60, HT
showed a maximum dose to the target (Dmax) closer to the
prescription dose [78.1+ 2.7 vs. 82.0+ 5.6 for PTV70 (P ¼
0.002); 76.2+ 2.4 vs. 82.0+ 5.7 for PTV60 (P, 0.0001)],
lower hot-points (V107%) [24.4+ 22.3 vs. 44.9+ 20.8 for
PTV70 (P ¼ 0.001); 42.4+ 22.3 vs. 71.4+ 15.3 for PTV60
(P, 0.0001)] and superior uniform target coverage (UI)
[1.11 vs. 1.13 for PTV70 (P ¼ 0.003); 1.20 vs. 1.23 for
PTV60 (P ¼ 0.001)] compared with ssIMRT. The differences
Table 3. Comparison of dose-volume histogram parameters by radiotherapy modality
DVH parameters ssIMRT (n ¼ 28) HT (n ¼ 25) Total (n ¼ 53) P value
PTV70
Dmax (Gy) 82.0+5.6 78.1+2.7 80.2+4.8 0.002
Dmin (Gy) 55.9+9.2 56.9+9.7 56.4+9.4 0.706
V95% (%) 98.4+2.9 99.3+0.8 98.8+2.2 0.111
V107% (%) 44.9+20.8 24.4+22.3 35.3+23.7 0.001
Median UI (range) 1.13 (1.07–1.25) 1.11 (1.01–1.16) 1.12 (1.01–1.25) 0.003
PTV60
Dmax (Gy) 82.0+5.7 76.2+2.4 79.3+5.3 ,0.0001
Dmin (Gy) 33.6+5.6 33.1+9.4 33.4+7.6 0.805
V95% (%) 96.1+3.7 96.4+5.5 96.3+4.6 0.868
V107% (%) 71.4+15.3 42.4+22.3 57.7+23.7 ,0.0001
Median UI (range) 1.23 (1.07–1.62) 1.20 (1.09–1.63) 1.25 (1.09–1.63) 0.001
DVH, dose-volume histogram; PTV70, planning target volume receiving 70 Gy; Dmax, maximum dose; Dmin, minimum dose; V95%, PTV receiving .95% of
the prescribed dose; V107%, PTV receiving .107% of the prescribed dose; UI, uniformity index; ssIMRT, step-and-shoot intensity modulated radiotherapy;
HT, helical tomotherapy.
Table 4. Dose distribution for organs at risk (n ¼ 53)
OARs ssIMRT (n ¼ 28) HT (n ¼ 25) Total (n ¼ 53) P value
Spinal cord
Dmax (Gy) 41.72+7.46 40.39+7.06 41.09+7.24 0.507
Brain stem
Dmax (Gy) 49.88+6.98 51.89+11.80 50.83+9.52 0.462
Optic chiasm
Dmax (Gy) 37.62+16.40 38.19+17.66 37.91+16.81 0.923
Rt. inner ear
Dmax (Gy) 41.44+8.45 45.68+8.45 43.77+9.52 0.124
Dmean (Gy) 29.02+8.14 29.70+8.53 29.34+8.25 0.778
Lt. inner ear
Dmax (Gy) 41.11+8.02 47.28+11.96 43.87+10.33 0.041
Dmean (Gy) 28.90+7.47 30.59+10.72 29.66+9.0 0.530
Rt. parotid gland
Dmean (Gy) 20.75+3.08 23.01+5.39 21.81+4.43 0.072
D50 (Gy) 19.16+4.55 20.30+6.04 19.70+5.28 0.439
V30 (%) 18.95+12.85 21.36+15.59 20.08+14.12 0.540
Lt. parotid gland
Dmean (Gy) 20.51+3.19 23.56+6.80 21.95+5.39 0.048
D50 (Gy) 19.25+3.69 20.80+6.57 19.98+5.25 0.304
V30 (%) 17.18+11.82 23.44+20.24 20.13+16.48 0.170
OARs, organs at risk; D50, dose to 50% of parotid volume; V30, parotid
volume receiving .30 Gy.
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were statistically signiﬁcant. Comparison of the dose distri-
bution for OARs showed no signiﬁcant differences between
the two modalities, except for Dmax to the left inner ear and
Dmean to the left parotid gland, for which ssIMRT was super-
ior (Table 4). HT showed a trend for improved dermatitis
and xerostomia, although the differences were not signiﬁcant
between ssIMRT and HT (Table 5). Table 6 shows the com-
parison of clinical parameters and treatment outcomes
among patients treated by ssIMRT and HT. N3 stage was
more frequently found among the patients treated with HT (2
vs. 11%, P ¼ 0.028), and more patients were treated with
IC þ CCRT in the HT group (2 vs. 11%, P ¼ 0.028). The
rates of 5-year local control, locoregional control, disease-
free survival and overall survival between ssIMRT and HT
were 93 vs. 89%, 89 vs. 85%, 77 vs. 66% and 85 vs. 83%.
The differences were not statistically signiﬁcant.
DISCUSSION
NPC is primarily treated by radiation alone or CCRT and
locoregional control through optimized radiation treatment
remains an important goal. IMRT allows the delivery of
increased dose of radiation to the tumor with a high degree
of conformity, while sparing adjacent critical normal organs.
IMRT is highly effective in delivering SIB for HNC cases.
Convenience of a single-phase planning is not the only ad-
vantage of IMRT-SIB. The true advantage is in increasing
the therapeutic ratio by permitting the differential delivery of
escalated daily fraction sizes speciﬁcally to the gross disease
and standard fraction sizes to the electively treated clinical
target volumes, while effectively sparing adjacent critical
organs. IMRT-SIB also allows greater conformity compared
with other IMRT techniques. In a plan comparison study
(20), IMRT-SIB achieved improved normal tissue sparing
compared with sequential delivery of IMRT boost after
either whole neck IMRT or conventional ﬁelds. The poten-
tial role of IMRT-SIB in improving local control through a
moderate acceleration of the treatment has been identiﬁed in
several HNC studies including nasopharyngeal cancer (20–23).
In the current study, IMRT-SIB was used to treat all patients.
Table 5. Toxicities by RTOG/WHO criteria
Toxicity ssIMRT
(n ¼ 28)
HT
(n ¼ 25)
Total
(n ¼ 53)
P value
No. % No. % No. %
Acute
Mucositis 0.406
Grade 0 0 0 0 0 0 0
Grade 1 5 17.9 7 28.0 12 22.6
Grade 2 16 57.1 15 60.0 31 58.5
Grade 3 7 25.0 3 12.0 10 18.9
Grade 4 0 0 0 0 0 0
Dermatitis 0.054
Grade 0 0 0 0 0 0 0
Grade 1 15 53.6 21 84.0 36 67.9
Grade 2 12 42.9 4 16.0 16 30.2
Grade 3 1 3.6 0 0 1 1.9
Grade 4 0 0 0 0 0 0
Leukopenia 0.551
Grade 0 6 21.4 3 12.0 9 17.0
Grade 1 9 32.1 13 52.0 22 41.5
Grade 2 11 39.3 8 32.0 19 35.8
Grade 3 1 3.6 1 4.0 2 3.8
Grade 4 1 3.6 0 0 1 1.9
Late
Xerostomia 0.055
Grade 0 6 21.4 13 52.0 19 35.8
Grade 1 12 42.9 8 32.0 20 37.7
Grade 2 10 35.7 4 16.0 14 26.4
Grade 3 0 0 0 0 0 0
Grade 4 0 0 0 0 0 0
RTOG, Radiation Therapy Oncology Group.
Table 6. Comparison of clinical factors and treatment outcome by
radiotherapy modality
Clinical parameters ssIMRT (n ¼ 28) HT (n ¼ 25) P value
Pathology 0.027
WHO I 2 (3.8%) 0 (0)
WHO IIa 9 (17.0%) 2 (3.8%)
WHO IIb 17 (32.1%) 23 (43.4%)
T stage 0.707
T1–T2 16 (30.2%) 13 (24.5%)
T3–T4 12 (22.6%) 12 (22.6%)
N stage 0.028
N0–2 27 (50.9%) 19 (35.8%)
N3 1 (1.9%) 6 (11.3%)
Overall stage 0.862
IIB 4 (7.5%) 4 (7.5%)
III–IVB 24 (45.3%) 21 (39.6%)
Treatment 0.028
CCRT 27 (50.9%) 19 (35.8%)
IC þ CCRT 1 (1.9%) 6 (11.3%)
5-year LCR 92.7% (83–100%) 88.6% (73–100%) 0.796
5-year LRCR 89.0% (77–100%) 84.9% (68–100%) 0.711
5-year DFS 76.8% (60–93%) 66.2% (45–88%) 0.196
5-year OS 84.6% (70–99%) 82.8% (67–98%) 0.542
LCR, local control rate; LRCR, locoregional control rate; DFS, disease-free
survival; OS, overall survival.
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Forty-nine patients (92.5%) showed a complete clinical and
radiographic response at 3 months after initial treatment and
2 patients showed a partial response. The 3- and 5-year local
control and locoregional control rates were 91.8 and 91.8%,
and 87.6 and 87.6%, respectively, showing the durable effect
of treatment on disease control. The result of the current
study is comparable to 2–4-year local control rates of 88–
98% in the other SIB-IMRT studies for nasopharyngeal
cancer (10,21,24,25) and signiﬁcantly higher than 2-year
local control of 54–67% from other clinical trials involving
delayed concomitant boost for HNC treatment (26,27).
IMRT-SIB is advantageous with respect to counteracting
the effects of accelerated tumor repopulation through several
mechanisms. It had been demonstrated that the prolongation
of the overall treatment time in laryngeal cancer may result
in a loss of local control of 1% per extra day (28).
Moderate hypofractionation through SIB shortens the overall
treatment time by several days or up to 1 week, and patients
will beneﬁt from improved local control without signiﬁcantly
increased toxicity. Early initiation of boost schedule may
also improve local control, as IMRT-SIB allows the delivery
of the boost dose from the beginning of radiotherapy.
Terhaard et al. (29) demonstrated that a concomitant boost in
week 3 compared with a boost in week 4 of the treatment
schedule improved 3-year local control rate from 59 to 78%,
with a notion that the accelerated repopulation had occurred
sooner than expected and was counteracted by an early start
of the boost schedule. NPC has a higher tendency of cervical
lymph node metastasis compared with other HNCs. The
early boost to individual metastatic cervical lymph nodes
may account for the high control rate of regional disease in
the current study. Another mechanism of improving local
control is through more effective killing of cancer stem cells
with larger fraction sizes. An increasing amount of evidence
suggests that failure to eradicate cancer stem cells leads to
tumor recurrence. Cancer stem cells, that are tumorigenic
and capable of self-renewal, have been isolated from head
and neck squamous cell carcinoma (11) and shown to be
more radioresistant (12). Recently CD44þ cells with bio-
logical characteristics of tumor stem cells have been isolated
from human NPC cell line (30).
In the current study, seven patients (13.2%) showed
distant metastases at 4–48 months (median: 21) after treat-
ment, while locoregional failure was observed in six patients
(11.3%). The distant metastasis free survival (DMFS) rates
of 89.7 and 81.9% at 3 and 5 years, respectively (results not
shown), are comparable to the results of other studies involv-
ing accelerated RT with concurrent chemotherapy for naso-
pharyngeal cancer, where 3-year DMFS ranged from 79 to
90% (23,25). Although the addition of chemotherapy
improves the treatment outcome of locally advanced NPC,
toxicities such as hematologic toxicity and oral mucositis in-
crease in the CCRT setting (31). Our study, however,
demonstrated that the use of IMRT was highly effective in
reducing acute and late toxicities such as Grade 3 or higher
mucositis and xerostomia.
HT is an advanced form of IMRT. While ssIMRT delivers
5–9 intensity-modulated radiation beams at ﬁxed gantry
angles, HT utilizes a system of 3608 rotational gantry and
sliding patient couch resulting in the delivery of multiple
intensity-modulated beams in a helical motion. Plan com-
parison studies between conventional IMRT and HT have
shown superior dose conformity for PTV and dose sparing
of OARs by HT (16,18,32). Lee et al. (18) compared
ssIMRT and HT plans for nasopharyngeal cancer patients.
SIB technique was used where 72, 64.8 and 54 Gy were pre-
scribed to PTV, elective PTV and clinically negative neck
regions, respectively. HT plans signiﬁcantly improved the
conformity index (improvement ratio: 11.9+ 5.5%), homo-
geneity index (improvement ratio: 8.8+ 1.5%) and sparing
of OARs compared with ssIMRT plans. In the current study,
28 patients were treated with ssIMRT and 25 patients with
HT. In dosimetric comparison, HT showed the maximum
dose to target (Dmax) closer to the prescription dose, lower
hot-point (V107%) and superior UI coverage compared with
ssIMRT for both PTV70 and PTV60. The current study is not
to show a direct plan comparison between ssIMRT and HT,
since the two treatment plans had not been generated on
identical patients. However, a single protocol of targeting
and dose prescription was used for both ssIMRT and HT
planning, and comparison of dosimetric parameters sug-
gested superiority of HT in the clinical setting. Comparison
of treatment outcome between ssIMRT and HT showed no
signiﬁcant difference in terms of local and locoregional
control and patient survival. However, it is to be noted that
the locoregional control rates of ssIMRT and HT were com-
parable in spite of the higher incidence of N3 disease among
the patients treated with HT. We also noted that patients in
the HT group did not report increased rate of mucositis
despite the fact that most of the IC þ CCRT cases (6/7)
belonged to the HT group. We concluded that both ssIMRT
and HT are highly effective in tumor control and sparing of
normal organs for the treatment of NPC patients. Target
volumes of more complicated shapes, stricter dose con-
straints for normal organs and longer follow-up periods are
required to discriminate the two IMRT modalities in terms
of clinical outcome.
A weakness of the current study is that a variety of chemo-
therapy schedule was used including three different CCRT
regimens and IC administered in seven patients. However, all
patients received concurrent chemotherapy in the current
study, and we expect that locoregional control is mostly a
result of adequate radiation coverage with concomitant boost
through IMRT-SIB. A prospective trial with a uniform proto-
col of combined modality treatment is required to accurately
assess the role of IMRT-SIB in locoregional control of NPC.
Moderately accelerated radiotherapy through IMRT-SIB
with concurrent chemotherapy was well tolerated and highly
efﬁcacious for the treatment of NPC, resulting in durable
locoregional control and minimized toxicity. Further accu-
mulation of clinical data is required to compare treatment
outcomes between conventional IMRT and HT.
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